

8 October 2018

NSX Announcement

ISSUE OF SHARES FOR MEDICINE PLUS

Beroni Group Limited (NSX:BTG) (“Beroni” or “the Company”) is pleased to announce that, further to its announcement on 21 September 2018 and in consideration for extending the due date for completion, it has agreed with the shareholders of Medicine Plus Co., Ltd (“MP”) to issue 2,067,900 fully paid ordinary shares and 7,030 convertible notes as part payment of approximately A\$15.8m consideration for 100% of issued shares in MP (“Acquisition”). As announced on 21 September 2018, the Acquisition consideration has been adjusted in exchange for two months extension of the Acquisition completion date.

By an amendment agreement dated 5 October 2018, 2,067,900 fully paid ordinary shares will be issued at a deemed issue price of \$1.75 per share. Beroni will seek to raise new funds to pay the remaining cash component of the Consideration of approximately JPY 1.0013 billion (or A\$12.2 million¹) by 20 November 2018. In the event Beroni makes the payment on or before 20 November and the Acquisition completes, the 7,030 convertible notes will be redeemed and cancelled for a nominal cost. However, in the event Beroni does not make the cash payment by 20 November and the Acquisition does not complete, MP’s shareholders will retain all of the 2,067,900 ordinary shares issued, and the 7,030 convertible notes will be redeemed and cancelled at a nominal cost; with the parties having no further obligations under the Acquisition.

The shares will be issued without shareholder approval and using Beroni’s existing 15% capacity under Listing Rule 6.25. Beroni will continue to update shareholders on the proposed Acquisition and the associated fund raising activities.

¹ Exchange rate of A\$1 = JPY 82 used to convert JPY amount

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Executive Director and CFO
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG)

Beroni Group is a Chinese biotechnological company which is listed on the National Stock Exchange of Australia. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.